featured
Safety and Antitumour Activity of the Anti–PD-1/CTLA-4 Bispecific Antibody Cadonilimab in Patients With Advanced Solid Tumours
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
Lancet Oncol 2023 Oct 01;24(10)1134-1146, X Gao, N Xu, Z Li, L Shen, K Ji, Z Zheng, D Liu, H Lou, L Bai, T Liu, Y Li, Y Li, Q Fan, M Feng, H Zhong, Y Huang, G Lou, J Wang, X Lin, Y Chen, R An, C Li, Q Zhou, X Huang, Z Guo, S Wang, G Li, J Fei, L Zhu, H Zhu, X Li, F Li, S Liao, Q Min, L Tang, F Shan, J Gong, Y Gao, J Zhou, Z Lu, X Li, J Li, H Ren, X Liu, H Yang, W Li, W Song, ZM Wang, B Li, M Xia, X Wu, J JiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.